Cardinal Health, Inc. raised its earnings guidance for fiscal year 2024. For the period, the company expects non-GAAP diluted earnings per share attributable to $7.30 to $7.40, from $7.20 to $7.35. This guidance includes an update to the company?s Pharmaceutical and Specialty Solutions segment profit outlook to 8.5% to 9.5% growth, from 7% to 9% growth.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
101.1 USD | -1.97% | -3.13% | +0.30% |
06-14 | Merit Medical is recalling unauthorized plastic syringes, US FDA says | RE |
06-14 | Deutsche Bank Adjusts Cardinal Health Price Target to $115 From $110 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.30% | 25.12B | |
+29.50% | 78.4B | |
+14.70% | 8.62B | |
+2.20% | 8.55B | |
-28.87% | 6.91B | |
+16.06% | 5.34B | |
+1.58% | 4.17B | |
-8.90% | 3.82B | |
-7.62% | 3.37B | |
+9.36% | 3.26B |
- Stock Market
- Equities
- CAH Stock
- News Cardinal Health, Inc.
- Cardinal Health, Inc. Raises Its Earnings Guidance for Fiscal Year 2024